The DOI matches its Crossref record.
Mortality in a cohort of long‐term users of hormone replacement therapy: an updated analysis
Abstract
Objective.–To reexamine the mortality experience of a cohort of long‐term users of hormone replacement therapy (HRT) in comparison with that reported previously for the same cohort of women, paying particular attention to cardiovascular mortality, deaths from breast and endometrial cancer, and deaths attributed to suicide or suspected suicide. Design–Longitudinal cohort of 4544 long‐term users of HRT amongst whom mortality is being monitored prospectively in comparison with expected rates in the female population of England and Wales (taking account of age and calendar period). Subjects–4544 women, all of whom were recruited from specialist menopause clinics around Britain and had taken at least one year's continuous HRT at the time of recruitment to the study. Main outcome measures–All cause mortality, cardiovascular mortality, deaths from female cancers, deaths attributed to suicide or suspected suicide. Results–Overall mortality (based on 236 deaths over the entire study period from recruitment to December 1988) remained significantly lower than expected on the basis of national rates (relative risk (RR) 0.56,95% confidence limits (CL) 0.47‐0.66). When specific causes were considered, the only mortality ratios greater than unity were for injury, poisoning and violence (1.54, 95% CL 1.02‐2.06), and for suicide and suspected suicide (‘suicide’) (2.40, 95% CL 1.68‐3 .11). Comparison of the ratios for the 112 additional deaths with those obtained in our previous analysis revealed that one of the few ratios to show any increase was that for breast cancer mortality. This rose from a significant deficit of 0.55 (95% CL 0.28‐0.96) in the earlier period to 1.00 (95% CL 0.55‐1.45) in the later period. There was also a suggestion of an increase in breast cancer risk with increasing duration since first use of HRT. Most of the other cause‐specific ratios were very similar over the two periods. The ratio of death from all circulatory diseases was notably lower in the later analysis (RR 0.37,95% CL 0.15‐0.58) than in the earlier analysis (0.51, 95% CL 0.36‐0.69), as were all of the subcategories of cardiovascular death. The mortality ratio for cancer of the ovary and uterine adnexa fell from 1.12 in the previous analysis to 0.63 (95% CL 0‐1.41). The mortality ratio for ‘suicide’ also decreased, but was only slightly lower in the later period. As before, however, there was evidence of a relatively high prevalence of prior psychiatric problems amongst the recent ‘suicide’ deaths, suggesting that the excess of deaths from ‘suicide’ may be a manifestation of selection. Conclusion–These data are consistent with a benelicial effect of HRT on cardiovascular diseases, although updated information comparing progestogen‐opposed and ‐unopposed treatmcnt is not available. The increase in breast cancer mortality contrasts with the pattern for all other specific causes examined; taken together with the suggestion of an increase in breast cancer mortality with increasing interval since first exposure to HRT, this finding is somewhat worrying.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women
Grady, D., Rubin, S. M., Petitti, D. B., Fox, C. S., Black, D., Ettinger, B., Ernster, V. L., & Cummings, S. R. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-12-1016 · Cited by 2,336
Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease
Grodstein, F., Stampfer, M. J., Manson, J. E., Colditz, G. A., Willett, W. C., Rosner, B., Speizer, F. E., & Hennekens, C. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608153350701 · Cited by 1,305
Wassertheil-Smoller, S., Hendrix, S., Limacher, M., Heiss, G., Kooperberg, C., Baird, A., Kotchen, T., Curb, J. D., Black, H., Rossouw, J. E., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2673 · Cited by 1,159
Hormone replacement therapy and endometrial cancer risk: A meta-analysis
GRADY, D., GEBRETSADIK, T., KERLIKOWSKE, K., ERNSTER, V, & PETITTI, D. (1995) · Obstetrics & Gynecology · doi:10.1016/0029-7844(94)00383-o · Cited by 962
A Clinical Trial of Estrogen-Replacement Therapy after Ischemic Stroke
Viscoli, C. M., Brass, L. M., Kernan, W. N., Sarrel, P. M., Suissa, S., & Horwitz, R. I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010534 · Cited by 921
Metadata
- Authors
- HUNT, K., VESSEY, M., & McPHERSON, K.
- Venue
- BJOG: An International Journal of Obstetrics & Gynaecology
- Publisher
- Wiley
- Published
- 1990-12
- Volume
- 97
- Issue
- 12
- Pages
- 1080-1086
- ISSN
- 0306-5456 (ISSN-L)
- 1470-0328
- 1471-0528
- OpenAlex
- W2141450021
- Cited by
- 228
- References
- 0
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mortality in a cohort of long‐term users of hormone replacement therapy: an updated analysis. https://app.cochat.ai/papers/10.1111/j.1471-0528.1990.tb02494.x
- The paper
- HUNT, K., VESSEY, M., & McPHERSON, K. (1990). Mortality in a cohort of long‐term users of hormone replacement therapy: an updated analysis. BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/j.1471-0528.1990.tb02494.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.